<DOC>
	<DOCNO>NCT00669916</DOCNO>
	<brief_summary>This two-arm , parallel group , double-blind , placebo-controlled proof-of-concept study compare 3 mg/kg AIN457 placebo . Subjects diagnosis moderate severe stable plaque psoriasis randomize receive either AIN457 placebo . AIN457 placebo administer single infusion baseline subject observed 26 week follow infusion .</brief_summary>
	<brief_title>A Study Comparing AIN457 Placebo Subjects With Diagnosis Moderate Severe Stable Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Males female , age 1869 time consent . Post menopausal surgically sterile female patient allow . Male patient must willing use contraception method least 3 month follow completion study . Women childbearing potential allow participate . Diagnosis plaque psoriasis least 6 month prior screen . The patient must meet following criterion : 1 . Coverage body surface area ( BSA ) 10 % plaque 2 . A score 3 IGA scale Stable plaque psoriasis screen randomization . PASI score 12 great randomization . Able communicate well investigator , understand comply requirement study . Understand sign write informed consent . Patients must normal laboratory value screen laboratory test result hematological ( hemoglobin , WBCs , neutrophils , platelet ) renal ( serum creatinine ) assessment . For transaminase , aspartate aminotransferase alanine aminotransferase , level 1.5 time upper limit normal accept . For additional hepatic laboratory result ( alkaline phosphatase , gammaglutamyltransferase , bilirubin ) , patient must nonclinically significant value . Currently nonplaque form psoriasis : erythrodermic , guttate , pustular . Currently druginduced psoriasis ( new onset exacerbation psoriasis beta blocker , calcium channel blocker , lithium ) . Men plan initiate pregnancy enrol study 3 month follow completion study . Women childbearing potential allow study . Used investigational drug within previous 4 week . Recent previous treatment antiTNFÎ± therapy ( biological therapy ) , immunosuppressive agent cyclosporine , mycophenolate , pimecrolimus , tacrolimus . The follow washout period require patient eligible participate trial . 1 . 2 month washout prior screening etanercept , adalimumab , infliximab . 2 . 1 month washout prior screen cyclosporine , mycophenolate , tacrolimus , systemic immunosuppressant include , limited , methotrexate , azathioprine , 6thioguanine , mercaptopurine , hydroxyurea Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Plaque psoriasis</keyword>
</DOC>